Erythrocebus patas monkey offspring exposed perinatally to NRTIs sustain skeletal muscle mitochondrial compromise at birth and at 1 year of age

Toxicological Sciences

Volumn 99, Issue 1, 2007, Pages 203-213

  Divi, Rao L ^a   Leonard, Sarah L ^a   Walker, Brettania L ^a   Kuo, Maryanne M ^a   Shockley, Marie E ^a   St Claire, Marisa C ^b   Nagashima, Kunio ^c   Harbaugh, Steven W ^b   Harbaugh, Jeffrey W ^b   Poirier, Miriam C ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b BIOQUAL INC   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Didanosine; Electron microscopy; Lamivudine; Mitochondrial DNA quantity; Oxidative phosphorylation; Stavudine; Zidovudine

Indexed keywords

CREATINE KINASE; CYTOCHROME C OXIDASE; DIDANOSINE; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; MITOCHONDRIAL DNA; RANITIDINE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; SUCCINATE DEHYDROGENASE (UBIQUINONE); ZIDOVUDINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIRTH; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ELECTRON MICROSCOPY; ENZYME ACTIVITY; ERYTHROCEBUS; FEMALE; GESTATIONAL AGE; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; MITOCHONDRIAL DNA DEPLETION; MONKEY; MYOPATHY; NEWBORN; NONHUMAN; NUCLEOTIDE SEQUENCE; OXIDATIVE PHOSPHORYLATION; PERINATAL DRUG EXPOSURE; PROGENY; SKELETAL MUSCLE; TOXICITY TESTING;

ANIMALS; ANIMALS, NEWBORN; ANTI-HIV AGENTS; CREATINE KINASE; DNA, MITOCHONDRIAL; DRUG THERAPY, COMBINATION; ERYTHROCEBUS PATAS; FEMALE; GESTATIONAL AGE; HISTOCYTOCHEMISTRY; MATERNAL EXPOSURE; MICROSCOPY, ELECTRON, TRANSMISSION; MITOCHONDRIA, MUSCLE; MULTIENZYME COMPLEXES; MUSCLE, SKELETAL; PREGNANCY; REVERSE TRANSCRIPTASE INHIBITORS;

ERYTHROCEBUS PATAS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 34547890659     PISSN: 10966080     EISSN: 10960929     Source Type: Journal    
DOI: 10.1093/toxsci/kfm143     Document Type: Article

References (36)

1. Barret, B., Tardieu, M., Rustin, P., Lacroix, C., Chabrol, B., Desguerre, I., Dollfus, C., Mayaux, M. J., and Blanche, S. (2003). Persistent mitochondrial dysfunction in HIV-1-exposed but uninfected infants: Clinical screening in a large prospective cohort. AIDS 17, 1769-1785.
2. Beach, J. W. (1998). Chemotherapeutic agents for human immunodeficiency virus infection: Mechanism of action, pharmacokinetics, metabolism, and adverse reactions. Clin. Ther. 20, 2-25.
3. Birch-Machin, M. A., Briggs, H. L., Saborido, A. A., Bindoff, L. A., and Turnbull, D. M. (1994). An evaluation of the measurement of the activities of complexes I-IV in the respiratory chain of human skeletal muscle mitochondria. Biochem. Med. Metab. Biol. 51, 35-42.
4. Birch-Machin, M. A., and Turnbull, D. M. (2001). Assaying mitochondrial respiratory complex activity in mitochondria isolated from human cells and tissues. Methods Cell Biol. 65, 97-117.
5. Blanche, S., Tardieu, M., Rustin, P., Slama, A., Barret, B., Firtion, G., Ciraru-Vigneron, N., Lacroix, C., Rouzioux, C., Mandelbrot, L., et al. (1999). Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues. Lancet 354, 1084-1089.
6. Bradford, M. M. (1976). A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72, 248-254.
7. Brinkman, K. (2001). Management of hyperlactatemia: No need for routine lactate measurements. AIDS 15, 795-797.
8. Brogly, S. B., Ylitalo, N., Mofenson, L. M., Oleske, J., van Dyke, R., Crain, M. J., Abzug, M. J., Brady, M., Jean-Philippe, P., Hughes, M. D., et al. (2007). In utero nucleoside reverse transcriptase inhibitor exposure and signs of possible mitochondrial dysfunction in HIV-uninfected children. AIDS 21, 929-938.
9. Caselli, D., Klersy, C., de Martino, M., Gabiano, C., Galli, L., Tovo, P. A., and Arico, M. (2000). Human immunodeficiency virus-related cancer in children: Incidence and treatment outcome-report of the Italian Register. J. Clin. Oncol. 18, 3854-3861.
10. Connor, E. M., Sperling, R. S., Gelber, R., Kiselev, P., Scott, G., O'Sullivan, M. J., VanDyke, R., Bey, M., Shearer, W., Jacobson, R. L., et al. (1994). Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N. Engl. J. Med. 331, 1173-1180.
11. Culnane, M., Fowler, M., Lee, S. S., McSherry, G., Brady, M., O'Donnell, K., Mofenson, L., Gortmaker, S. L., Shapiro, D. E., Scott, G., et al. (1999). Lack of long-term effects of in utero exposure to zidovudine among uninfected children born to HIV-infected women. Pediatric AIDS Clinical Trials Group Protocol 219/076 Teams. [see comments] JAMA 281, 151-157
12. Dagan, T., Sable, C., Bray, J., and Gerschenson, M. (2002). Mitochondrial dysfunction and antiretroviral nucleoside analog toxicities: What is the evidence? Mitochondrion 1, 397-412.
13. Dalakas, M. C., Illa, I., Pezeshkpour, G. H., Laukaitis, J. P., Cohen, B., and Griffm, J. L. (1990). Mitochondrial myopathy caused by long-term zidovudine therapy. N. Engl. J. Med. 322, 1098-1105.
14. Divi, R. L., Leonard, S. L., Kuo, M. M., Nagashima, K., Thamire, C., St Claire, M. C., Wade, N. A., Walker, V. E., and Poirier, M. C. (2007). Transplacentally exposed human and monkey newborn infants show similar evidence of nucleoside reverse transcriptase inhibitor-induced mitochondrial toxicity. Environ. Mol. Mutagen. 48, 201-209.
15. Divi, R. L., Leonard, S. L., Kuo, M. M., Walker, B. L., Orozco, C. C., St Claire, M. C., Nagashima, K., Harbaugh, S. W., Harbaugh, J. W., Thamire, C., et al. (2005). Cardiac mitochondrial compromise in 1-yr-old Erythrocebus patas monkeys perinatally-exposed to nucleoside reverse transcriptase inhibitors. Cardiovasc. Toxicol. 5, 333-346.
16. Divi, R. L., Walker, V. E., Wade, N. A., Nagashima, K., Seilkop, S. K., Adams, M. E., Nesel, C. J., O'Neill, J. P., Abrams, E. J., and Poirier, M. C. (2004). Mitochondrial damage and DNA depletion in cord blood and umbilical cord from infants exposed in utero to Combivir. AIDS 18, 1013-1021.
17. Gerard, Y., Maulin, L., Yazdanpanah, Y., De, L. T. X., Amiel, C., Maurage, C. A., Robin, S., Sablonniere, B., Dhennain, C., and Mouton, Y. (2000). Symptomatic hyperlactataemia: An emerging complication of antiretroviral therapy. AIDS 14, 2723-2730.
18. Gerschenson, M., Erhart, S. W., Paik, C. Y., St Claire, M. C., Nagashima, K., Skopets, B., Harbaugh, S. W., Harbaugh, J. W., Quan, W., and Poirier, M. C. (2000). Fetal mitochondrial heart and skeletal muscle damage in Erythrocebus patas monkeys exposed in utero to 3′-azido-3′-deoxythymidine (AZT). AIDS Res. Hum. Retroviruses 16, 635-644.
19. Gerschenson, M., Nguyen, V., Ewings, E. L., Ceresa, A., Shaw, J. A., St Claire, M. C., Nagashima, K., Harbaugh, S. W., Harbaugh, J. W., Olivero, O. A., et al. (2004). Mitochondrial toxicity in fetal Erythrocebus patas monkeys exposed transplacentally to zidovudine plus lamivudine. AIDS Res. Hum. Retroviruses 20, 91-100.
20. Hanson, I. C., Antonelli, T. A., Sperling, R. S., Oleske, J. M., Cooper, E., Culnane, M., Fowler, M. G., Kalish, L. A., Lee, S. S., McSherry, G., et al. (1999). Lack of tumors in infants with perinatal HIV-1 exposure and fetal/neonatal exposure to zidovudine. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 20, 463-467.
21. Lewis, W., and Dalakas, M. C. (1995). Mitochondrial toxicity of antiviral drugs. Nat. Med. 1, 417-422.
22. Lipshultz, S. E., Easley, K. A., Orav, E. J., Kaplan, S., Starc, T. J., Bricker, J. T., Lai, W. W., Moodie, D. S., Sopko, G., McIntosh, K., et al. (2000). Absence of cardiac toxicity of zidovudine in infants. Pediatric pulmonary and cardiac complications of Vertically Transmitted HIV Infection Study Group. N. Engl. J. Med. 343, 759-766.
23. Lu, L. J., Anderson, L. M., Jones, A. B., Moskal, T. J., Salazar, J. J., Hokanson, J. A., and Rice, J. M. (1993). Persistence, gestation stage-dependent formation and interrelationship of benzo[a]pyrene- induced DNA adducts in mothers, placentae and fetuses of Erythrocebus patas monkeys. Carcinogenesis 14, 1805-1813.
24. Mhiri, C., Baudrimont, M., Bonne, G., Geny, C., Degoul, F., Marsac, C., Roullet, E., and Gherardi, R. (1991). Zidovudine myopathy: A distinctive disorder associated with mitochondrial dysfunction. Ann. Neurol. 29, 606-614.
25. Mofenson, L.M. and Committee on Pediatric AIDS (2000). Technical Report: Perinatal human immunodeficiency virus testing and prevention of transmission. Pediatrics 106, 1-12
26. Mofenson, L. M., and Munderi, P. (2002). Safety of antiretroviral prophylaxis of perinatal transmission for HIV-infected pregnant women and their infants. J. Acquir. Immune Defic. Syndr. 30, 200-215.
27. Newschaffer, C. J., Cocroft, J., Anderson, C. E., Hauck, W. W., and Turner, B. J. (2000). Prenatal zidovudine use and congenital anomalies in a medicaid population. J. Acquir. Immune Defic. Syndr. 24 249-256.
28. Perinatal HIV Guidelines Working Group. Public Health Service Task Force Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1 Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV-1 Transmission in the United States, pp. 1-65. Available at: http://aidsinfo.nih.gov/ContentFiles/PerinatalGL.pdf. Accessed October 12, 2006.
29. Poirier, M. C., Divi, R. L., Al-Harthi, L., Olivero, O. A., Nguyen, V., Walker, B., Landay, A. L., Walker, V. E., Charurat, M., and Blattner, W. A. (2003). Long-term mitochondrial toxicity in HIV-uninfected infants born to HIV-infected mothers. J. Acquir. Immune Defic. Syndr. 33, 175-183.
30. Public Health Service Task Force Perinatal HIV Guidelines Working Group. (2002). Summary of the updated recommendations from the Public Health Service Task Force to reduce perinatal human immunodeficiency virus-1 transmission in the United States. Obstet. Gynecol. 99, 1117-1126.
31. Seligman, A. M., Karnovsky, M. J., Wasserkrug, H. L., and Hanker, J. S. (1968). Nondroplet ultrastructural demonstration of cytochrome oxidase activity with a polymerizing osmiophilic reagent, diaminobenzidine (DAB). J. Cell Biol. 38, 1-14.
32. Shiramizu, B., Shikuma, K. M., Kamemoto, L., Gerschenson, M., Erdem, G., Pinti, M., Cossarizza, A., and Shikuma, C. (2003). Placenta and cord blood mitochondrial DNA toxicity in HIV-infected women receiving nucleoside reverse transcriptase inhibitors during pregnancy. J. Acquir. Immune Defic. Syndr. 32, 370-374.
33. Sperling, R. S., Shapiro, D. E., Coombs, R. W., Todd, J. A., Herman, S. A., McSherry, G. D., O'Sullivan, M. J., Van Dyke, R. B., Jimenez, E., Rouzioux, C., et al. (1996). Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group [see comments]. N. Engl. J. Med. 335 1621-1629.
34. Tomelleri, G., Tonin, P., Spadaro, M., Tilia, G., Orrico, D., Barelli, A., Bonetti, B., Monaco, S., Salviati, A., and Morocutti, C. (1992). AZT-induced mitochondrial myopathy. Ital. J. Neurol. Sci. 13 723-728.
35. Trounce, I. A., Kim, Y. L., Jun, A. S., and Wallace, D. C. (1996). Assessment of mitochondrial oxidative phosphorylation in patient muscle biopsies, lymphoblasts, and transmitochondrial cell lines. Methods Enzymol. 264, 484-509.
36. Tuomala, R. E., Shapiro, D. E., Mofenson, L. M., Bryson, Y., Culnane, M., Hughes, M. D., O'Sullivan, M. J., Scott, G., Stek, A. M., Wara, D., et al. (2002). Antiretroviral therapy during pregnancy and the risk of an adverse outcome. N. Engl. J. Med. 346, 1863-1870.